Ischemia modified albumin in Patients with Obstructive Sleep Apnea Syndrome

Objective and aim: Ischemia-modified albumin (IMA) is a newly recognized risk marker for various diseases. We evaluated possible relationship between the ischemia-modified albumin (IMA) levels and severity scores obstructive sleep apnea syndrome (OSAS). Methods: Eighty-six patients and 83 controls were investigated by polysomnography (PSG) for OSAS. The patients were classified as a control group or as the OSAS group according to the apnea-hypopnea index (AHI). The IMA, C-reactive protein (CRP), hemogram analyses, and, Red Blood Cell Distribution Width (RDW) were measured. Results: The IMA values were higher in the OSAS group than in the controls (0.39±0.01 vs. 0.35±0.09, p = 0.019). The IMA values were higher in patients with cardiovascular diseases ( p Conclusion: In patients referred with a clinical diagnosis of OSAS, IMA may be a marker for the severity of the condition. IMA is independently associated with cardiovascular disease in patients with OSAS in our cross-sectional study